Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease

Pflugers Archiv European Journal of Physiology

Volumn 465, Issue 7, 2013, Pages 929-934

  Kuruppu, Sanjaya ^a   Rajapakse, Niwanthi W ^b   Smith, A Ian ^a  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cyclosporin A; Endothelin; Ischemia; Kidney; Puromycin aminonucleoside; Renal disease; Reperfusion

Indexed keywords

CHYMASE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; SM 19712; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; KIDNEY FAILURE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RENAL PROTECTION; REVIEW;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CHYMASES; ENDOTHELINS; ENZYME INHIBITORS; HUMANS; KIDNEY FAILURE, CHRONIC; METALLOENDOPEPTIDASES; NEPRILYSIN;

EID: 84879837764     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-013-1216-1     Document Type: Review

References (38)

1. Abassi ZA, Golomb E, Bridenbaugh R, Keiser HR (1993) Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br J Pharmacol 109(4):1024-1028
2. Cooper ME GR, Allen TJ (1998) Lessons from animal diabetes VII. In: A S (ed) Experimental diabetic nephropathy. Harwood Academic Publishers GmbH, Amsterdam, pp 207-223
3. Correa-Costa M, Azevedo H, Amano MT, Goncalves GM, Hyane MI, Cenedeze MA, Renesto PG, Pacheco-Silva A, Moreira-Filho CA, Camara NO (2012) Transcriptome analysis of renal ischemia/reperfusion injury and its modulation by ischemic pre-conditioning or hemin treatment. PLoS One 7(11):e49569. doi: 10.1371/journal.pone.0049569
4. D'Orleans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E (2008) Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. Vasc Pharmacol 49(2-3):51-62. doi: 10.1016/j.vph.2008.06.007
5. Disashi T, Nonoguchi H, Iwaoka T, Naomi S, Nakayama Y, Shimada K, Tanzawa K, Tomita K (1997) Endothelin converting enzyme-1 gene expression in the kidney of spontaneously hypertensive rats. Hypertension 30(6):1591-1597
6. Feldman DL, Mogelesky TC, Chou M, Jeng AY (2000) Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor. J Cardiovasc Pharmacol 36(5 Suppl 1):S342-S345
7. Frank K, Zeier M, Gross ML, Waldherr R, Ritz E, Amann K (2006) Comprehensive immunohistological analysis of the endothelin system in human kidney grafts. Nephrol Dial Transplant 21(5):1365-1372. doi: 10.1093/ndt/gfk087
8. Harrison-Bernard LM, Berner PM, Zhang X, Husain A, Naqvi N (2012) Abstract 393: chymase: augmented renal tubular protein expression in diabetes hypertension 60 (3):A393 to A393
9. Held HD, Raschak M, Uhlig S (1997) Rat big endothelin-1-induced bronchoconstriction and vasoconstriction in the isolated perfused rat lung: role of endothelin converting enzyme and neutral endopeptidase 24.11. Naunyn-Schmiedeberg's Archives of Pharmacology 355(5):619-624
10. Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter CM, Slowinski T, Sinha P, Neumayer HH (2003) Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol 14(9):2329-2337
11. Huang XR, Chen WY, Truong LD, Lan HY (2003) Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14(7):1738-1747
12. Ikebe M, Nonoguchi H, Nakayama Y, Tashima Y, Shimada K, Tanzawa K, Tomita K (2003) Regulation of endothelin-converting enzyme 1 in nephrotic syndrome in rats. Nephron Exp Nephrol 94(4):e137-e145. doi: 72497
13. Ishimura E, Sterzel RB, Morii H, Kashgarian M (1992) Extracellular matrix protein: gene expression and synthesis in cultured rat mesangial cells. Nihon Jinzo Gakkai Shi 34(1):9-17
14. Jandeleit-Dahm K, Allen TJ, Youssef S, Gilbert RE, Cooper ME (2000) Is there a role for endothelin antagonists in diabetic renal disease? Diabetes. Obes Metab 2(1):15-24
15. Kanwar YS, Sun L, Xie P, Liu FY, Chen S (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annual Review of Pathology 6:395-423. doi: 10.1146/annurev.pathol.4.110807.092150
16. Kerr MA, Kenny AJ (1974) The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137(3):477-488
17. Khamaisi M, Dahan R, Hamed S, Abassi Z, Heyman SN, Raz I (2009) Role of protein kinase C in the expression of endothelin converting enzyme-1. Endocrinology 150(3):1440-1449. doi: 10.1210/en.2008-0524
18. Khamaisi M, Raz I, Shilo V, Shina A, Rosenberger C, Dahan R, Abassi Z, Meidan R, Lecht S, Heyman SN (2008) Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney Int 74(1):91-100. doi: 10.1038/ki.2008.112
19. Korth P, Bohle RM, Corvol P, Pinet F (1999) Cellular distribution of endothelin-converting enzyme-1 in human tissues. J Histochem Cytochem 47(4):447-462
20. Kuruppu S, Tochon-Danguy N, Smith AI (2012) Protein kinase C recognition sites in the cytoplasmic domain of endothelin converting enzyme-1c. Biochem Biophys Res Commun 427(3):606-610. doi: 10.1016/j.bbrc.2012.09.105
21. Matsumura Y, Kuro T, Kobayashi Y, Umekawa K, Ohashi N, Takaoka M (2000) Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Japanese Journal of Pharmacology 84(1):16-24
22. Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, Loffler BM, Blum-Kaelin D, Masur S, Dehmlow H, Aebi JD, Haller H, Luft FC (2002) Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 40(6):840-846
23. Murphy LJ, Corder R, Mallet AI, Turner AJ (1994) Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol 113(1):137-142
24. Nambi P, Pullen M, Wu HL, Prabhakar U, Hersh L, Gellai M (1999) Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: possible mechanism for ischemia-induced acute renal failure in rats? Mol Cell Biochem 197(1-2):53-59
25. Ortmann J, Nett PC, Celeiro J, Hofmann-Lehmann R, Tornillo L, Terracciano LM, Barton M (2006) Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes. Exp Biol Med (Maywood) 231(6):1030-1033
26. Ozawa Y, Hasegawa T, Tsuchiya K, Yoshizumi M, Tamaki T (2003) Effect of endothelin-1 (1-31) on the renal resistance vessels. The Journal of Medical Investigation: JMI 50(1-2):87-94
27. Pupilli C, Romagnani P, Lasagni L, Bellini F, Misciglia N, Emoto N, Yanagisawa M, Rizzo M, Mannelli M, Serio M (1997) Localization of endothelin-converting enzyme-1 in human kidney. Am J Physiol 273(5 Pt 2):F749-F756
28. Rabelink TJ, Stroes ES, Bouter KP, Morrison P (1998) Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Cardiovasc Res 39(3):543-549
29. Russell FD, Coppell AL, Davenport AP (1998) In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharmacol 55(5):697-701
30. Sansoe G, Aragno M, Mastrocola R, Cutrin JC, Silvano S, Mengozzi G, Smedile A, Rosina F, Danni O, Rizzetto M (2006) Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis. American Journal of Physiology Renal Physiology 290(6):F1337-1343. doi: 10.1152/ajprenal.00435.2005
31. Sharma R, Prasad V, McCarthy ET, Savin VJ, Dileepan KN, Stechschulte DJ, Lianos E, Wiegmann T, Sharma M (2007) Chymase increases glomerular albumin permeability via protease-activated receptor-2. Mol Cell Biochem 297(1-2):161-169. doi: 10.1007/s11010-006-9342-0
32. Simard E, Jin D, Takai S, Miyazaki M, Brochu I, D'Orleans-Juste P (2009) Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 328(2):540-548. doi: 10.1124/jpet.108.142992
33. Smith AI, Lew RA, Thomas WG, Tochon-Danguy N (2006) Protein kinase C regulates the cell surface activity of endothelin-converting enzyme-1. Int J Pept Res Ther 12(3):291-295
34. Strait KA, Stricklett PK, Kohan JL, Miller MB, Kohan DE (2007) Calcium regulation of endothelin-1 synthesis in rat inner medullary collecting duct. American Journal of Physiology Renal Physiology 293(2):F601-606. doi: 10.1152/ajprenal.00085.2007
35. System USRD (2010) USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
36. Thone-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormahlen D, Hocher B (2004) Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol 44(Suppl 1):S76-S79
37. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163):411-415
38. Yasuoka H, Yoshizumi M, Inui D, Okishima N, Houchi H, Kirima K, Oshita S, Kido H, Tamaki T (1999) Effect of endothelin-1(1-31) on intracellular free calcium in cultured human mesangial cells. Life Sci 65(22):PL267-PL272